Non-animal methodologies within biomedical research and toxicity testing.
Laboratory animal models are limited by scientific constraints on human applicability, and increasing regulatory restrictions, driven by social concerns. Reliance on laboratory animals also incurs marked - and in some cases, prohibitive - logistical challenges, within high-throughput chemical testing programmes, such as those currently underway within Europe and the US. However, a range of non-animal methodologies is available within biomedical research and toxicity testing. These include: mechanisms to enhance the sharing and assessment of existing data prior to conducting further studies, and physicochemical evaluation and computerised modelling, including the use of structure-activity relationships and expert systems. Minimally-sentient animals from lower phylogenetic orders or early developmental vertebral stages may be used, as well as microorganisms and higher plants. A variety of tissue cultures, including immortalised cell lines, embryonic and adult stem cells, and organotypic cultures, are also available. In vitro assays utilising bacterial, yeast, protozoal, mammalian or human cell cultures exist for a wide range of toxic and other endpoints. These may be static or perfused, and may be used individually, or combined within test batteries. Human hepatocyte cultures and metabolic activation systems offer potential assessment of metabolite activity and organ-organ interaction. Microarray technology may allow genetic expression profiling, increasing the speed of toxin detection, well prior to more invasive endpoints. Enhanced human clinical trials utilising micro- dosing, staggered dosing, and more representative study populations and durations, as well as surrogate human tissues, advanced imaging modalities and human epidemiological, sociological and psycho- logical studies, may increase our understanding of illness aetiology and pathogenesis, and facilitate the development of safe and effective pharmacologic interventions. Particularly when human tissues are used, non-animal models may generate faster, cheaper results, more reliably predictive for humans, whilst yielding greater insights into human biochemical processes. Greater commitment to their development and implementation is necessary, however, to efficiently meet the needs of high-throughput chemical testing programmes, important emerging testing needs, and the ongoing development of human clinical interventions.
Knight
Andrew
A
Animal Consultants International, London, UK.
D000826:Animal Testing Alternatives / Q000941:ethics / Q000331:legislation & jurisprudence / Q000379:methods*; D000818:Animals; D035843:Biomedical Research / Q000941:ethics / Q000331:legislation & jurisprudence / Q000379:methods*; D002642:Chick Embryo; D004195:Disease Models, Animal; D064420:Drug-Related Side Effects and Adverse Reactions; D053595:Embryonic Stem Cells; D005103:Expert Systems; D005818:Genetic Engineering; D006801:Humans; D004364:Pharmaceutical Preparations / Q000737:chemistry; D013329:Structure-Activity Relationship; D046509:Tissue Culture Techniques; D018675:Toxicity Tests / Q000941:ethics / Q000379:methods*; D043922:Toxicogenetics
D004364:Pharmaceutical Preparations